JAMA
February 7, 2017, Vol 317, No. 5, Pages 453-546
http://www.jama.jamanetwork.com/issue.aspx

Viewpoint
Population Health Equity: Rate and Burden, Race and Class
David Kindig, MD, PhD
JAMA. 2017;317(5):467-468. doi:10.1001/jama.2016.19435
Although US racial and ethnic minorities have higher rates of poor health because of health care inequities, more low-income white individuals are affected because of greater population numbers. This Viewpoint explains that efforts to improve poor outcomes would be more effective if strategies were not based on proportions of race.

A Global Vaccine Injury Compensation System
Sam F. Halabi, JD, MPhil; Saad B. Omer, MBBS, MPH, PhD
JAMA. 2017;317(5):471-472. doi:10.1001/jama.2016.19492
This Viewpoint discusses the benefits of establishing a global vaccine injury compensation system that is government and manufacturer supported to compensate individuals who experience vaccine injury.

Privatized Pharmaceutical Innovation vs Access to Essential MedicinesA Global Framework for Equitable Sharing of Benefits
Gian Luca Burci; Lawrence O. Gostin, JD
JAMA. 2017;317(5):473-474. doi:10.1001/jama.2016.17994
This Viewpoint proposes a framework for promoting pharmaceutical innovation while ensuring access and affordability of new drugs on a global scale.

Equipoise in ResearchIntegrating Ethics and Science in Human Research
Alex John London, PhD
JAMA. 2017;317(5):525-526. doi:10.1001/jama.2017.0016
This JAMA Guide to Statistics and Methods article reviews the concept of equipoise, which allows for randomization of interventions while also respecting the rights of human subjects in clinical research.